title: [Cell cycle inhibitors in endocrine receptor positive breast cancer].
abstract: Dysregulation of cellular cycle is a key component of carcinogenesis and its targeting represents an interesting approach. Recently, the development of selective inhibitors of the cycle targeting the cyclin-dependent kinases (CDK) 4 and 6 revived interest in this therapeutic class after the failure of pan-inhibitors. Palbociclib, ribociclib, and abemaciclib are the 3 drugs with the most advanced development. They demonstrated preclinical activity in luminal breast cancer models and are under clinical evaluation. The first available studies demonstrate the value of these compounds with an improved prognosis of metastatic patients in combination with endocrine therapy (palbociclib, ribociclib) or in monotherapy (abemaciclib). The results of ongoing studies will clarify the role of these agents in our new strategies and the individualisation of biomarkers will help to define patients who benefit most from this approach.
authors.affiliation: Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France. Electronic address: mariepaule.sablin@curie.fr.
authors.forename: Marie-Paule
authors.initials: MP
authors.lastname: Sablin
authors.affiliation: Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: Francesco
authors.initials: F
authors.lastname: Ricci
authors.affiliation: Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: Delphine
authors.initials: D
authors.lastname: Loirat
authors.affiliation: Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: Aude
authors.initials: A
authors.lastname: Jobard
authors.affiliation: Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: Clémence
authors.initials: C
authors.lastname: Basse
authors.affiliation: Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: Emanuela
authors.initials: E
authors.lastname: Romano
authors.affiliation: Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Le Tourneau
authors.affiliation: Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: Véronique
authors.initials: V
authors.lastname: Dieras
mesh_terms: D000631:Aminopyridines / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D002453:Cell Cycle / Q000502:physiology; D059447:Cell Cycle Checkpoints; D002986:Clinical Trials as Topic; D051358:Cyclin-Dependent Kinase 4 / Q000037:antagonists & inhibitors* / Q000502:physiology; D051361:Cyclin-Dependent Kinase 6 / Q000037:antagonists & inhibitors* / Q000502:physiology; D005260:Female; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011687:Purines / Q000009:adverse effects / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000631:Aminopyridines; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011687:Purines; D011725:Pyridines; C000590451:abemaciclib; D051358:Cyclin-Dependent Kinase 4; D051361:Cyclin-Dependent Kinase 6; C500026:palbociclib; C000589651:ribociclib
keywords: Abemaciclib; Breast cancer; CDK4/6 inhibitors; Cancer du sein; Cellular cycle; Cycle cellulaire; Inhibiteurs de CDK4/6; Palbociclib; Ribociclib